IPHA CEO warns on reference drug pricing plans in Ireland
With the Irish government planning to introduce a bill for a reference pricing system in 2012, serious misgivings have been expressed about such a legislative development. Currently awaiting publication, the government has claimed that the new legislation will lead to a considerable reduction in the medicines bill for the state, an assertion that has been challenged by Anne Nolan, chief executive of the Irish Pharmaceutical Healthcare Association (IPHA).
Reflecting a widely held view among IPHA member companies, Ms Nolan has argued that there is no compelling evidence to suggest that the introduction of a reference pricing system, possibly accompanied by some form of generic substitution, will lead to savings for the state.
Investment and medicines availability at risk
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze